A Phase 1 interventional study of Vorinostat and Bortezomib in Multiple Myeloma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing vorinostat in Multiple Myeloma — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Multiple Myeloma.
Among the 19 studies testing vorinostat in Multiple Myeloma, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2009, is one of 10 in phase 1, and was the 12th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →None of the 19 studies testing vorinostat in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 8 · Phase 3 1
First in 2000; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 31 across the 17 interventional studies. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
20 studies in Multiple Myeloma by Merck & Co., Inc: none open now, 1 under way, none of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 20 studies in Multiple Myeloma by Merck & Co., Inc, this one is the 19th largest by enrollment, is one of 2 that started in 2009, is one of 14 in phase 1, and was the 10th registered.
Merck & Co., Inc’s Multiple Myeloma studies by the year they started, since 2000.
1 of the studies testing vorinostat in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01297764Hackensack Meridian HealthA Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing vorinostat in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 20 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this clinical study is to determine the recommended clinical doses of vorinostat (MK-0683) and bortezomib administered in combination to participants with relapsed and/or refractory multiple myeloma (MM). It was hypothesized that administration of vorinostat in combination with bortezomib is sufficiently safe and tolerated well enough to permit further study in participants with relapsed and/or refractory MM. Study results are based on data collected up to the data cut-off date of 20-March-2011.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo up to 3 successive 21-day treatment cycles. During Cycle 1, participants receive vorinostat (400 mg once daily \[QD\] on Days 1 through 14) + bortezomib (1.3 mg/m\^2 intravenous \[IV\] on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 2 participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 3 participants receive vorinostat (300 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\^2 IV on Days 1, 4, 8, and 11).
Drug: Vorinostat · Drug: Bortezomib
Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.
Also known as: MK-0683, ZOLINZA™
Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.
Also known as: VELCADE®
Number of Participants With Dose-Limiting Toxicity (DLT) During Cycle 1
The number of participants with ≥1 DLT during Cycle 1 is reported. A DLT is defined as an event considered by the investigator to be related to study treatment, and either: 1) a Grade 3 or 4 non-hematologic event (except for manageable toxicity by supportive care or non-prohibited therapies, or a transient increase in alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\]); or 2) a Grade 4 hematologic toxicity except neutropenia or hemoglobin decreased (neutropenia was a DLT if it was Grade 3-4 with fever ≥38.5°C; Grade 3-4 with an infection requiring antibiotic/antifungal therapy; or Grade 4 and lasting ≥5 days).
Time frame: Up to 21 days
Number of Participants With an Adverse Event (AE)
The number of participants with ≥1 AE is reported. An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product(s), whether or not considered related to the use of the product(s).
Time frame: Up to 346 days (up to 30 days after the final dose of study treatment)
Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Vorinostat Administered With Bortezomib on Days 1 and 11
The AUC0-24hr of vorinostat in plasma on Days 1 and 11 is reported in participants who also received bortezomib.
Time frame: Predose and 0.8, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 1 and 11
Adult male and female participants with relapsed and/or refractory multiple myeloma (MM) were enrolled at study sites in Japan.
| Milestone | Vorinostat + Bortezomib |
|---|---|
| Started | 9 |
| Completed | 0 |
| Not completed | 9 |
| Withdrew: Adverse event | 6 |
| Withdrew: Progressive disease | 2 |
| Withdrew: Status unknown | 1 |
The number of participants with ≥1 DLT during Cycle 1 is reported. A DLT is defined as an event considered by the investigator to be related to study treatment, and either: 1) a Grade 3 or 4 non-hematologic event (except for manageable toxicity by supportive care or non-prohibited therapies, or a transient increase in alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\]); or 2) a Grade 4 hematologic toxicity except neutropenia or hemoglobin decreased (neutropenia was a DLT if it was Grade 3-4 with fever ≥38.5°C; Grade 3-4 with an infection requiring antibiotic/antifungal therapy; or Grade 4 and lasting ≥5 days).
| Participants | Vorinostat + Bortezomib |
|---|---|
| Number of Participants With Dose-Limiting Toxicity (DLT) During Cycle 1 | 1 |
The number of participants with ≥1 AE is reported. An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product(s), whether or not considered related to the use of the product(s).
| Participants | Vorinostat + Bortezomib |
|---|---|
| Number of Participants With an Adverse Event (AE) | 9 |
The AUC0-24hr of vorinostat in plasma on Days 1 and 11 is reported in participants who also received bortezomib.
| µM*hr | Vorinostat + Bortezomib |
|---|---|
| Day 1 | 5.41 (4.33 to 6.77) |
| Day 11 | 5.84 (4.48 to 7.61) |
Collected over Up to 346 days (up to 30 days after the final dose of study treatment). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vorinostat + Bortezomib | 0/9 (0%) | 3/9 (33.3%) | 9/9 (100%) |
| Event | Vorinostat + Bortezomib |
|---|---|
| PneumoniaInfections and infestations | 2/9 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 1/9 |
| FatigueGeneral disorders | 1/9 |
| PyelonephritisInfections and infestations | 1/9 |
| SepsisInfections and infestations | 1/9 |
| Decreased appetiteMetabolism and nutrition disorders | 1/9 |
| Event | Vorinostat + Bortezomib |
|---|---|
| LeukopeniaBlood and lymphatic system disorders | 9/9 |
| NeutropeniaBlood and lymphatic system disorders | 9/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 9/9 |
| DiarrhoeaGastrointestinal disorders | 9/9 |
| NauseaGastrointestinal disorders | 8/9 |
| Decreased appetiteMetabolism and nutrition disorders | 8/9 |
| VomitingGastrointestinal disorders | 7/9 |
| LymphopeniaBlood and lymphatic system disorders | 6/9 |
| ConstipationGastrointestinal disorders | 6/9 |
| FatigueGeneral disorders | 5/9 |
| Age, Continuous(Years) | Vorinostat + Bortezomib |
|---|---|
| Mean | 63.3 ± 11.9 |
| Sex: Female, Male(Participants) | Vorinostat + Bortezomib |
|---|---|
| Female | 1 |
| Male | 8 |
| Race (NIH/OMB)(Participants) | Vorinostat + Bortezomib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 9 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2009 to primary completion in Jun 2010, 15 months.
Results were first posted in Apr 2021, 10 years 9 months after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 15 months is below that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vorinostat · Bortezomib